Tranexamic acid
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Tranexamic acid
| |
| Systematic (IUPAC) name | |
| 4-(aminomethyl)cyclohexane-1-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | B02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C8H15NO2 |
| Mol. mass | 157.21 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 34% |
| Metabolism | ? |
| Half life | 3.1 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
B |
| Legal status | |
| Routes | Injection and oral |
|
WikiDoc Resources for Tranexamic acid | |
|
Articles | |
|---|---|
|
Most recent articles on Tranexamic acid Most cited articles on Tranexamic acid | |
|
Media | |
|
Powerpoint slides on Tranexamic acid | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Tranexamic acid at Clinical Trials.gov Trial results on Tranexamic acid Clinical Trials on Tranexamic acid at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Tranexamic acid NICE Guidance on Tranexamic acid
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Tranexamic acid Discussion groups on Tranexamic acid Patient Handouts on Tranexamic acid Directions to Hospitals Treating Tranexamic acid Risk calculators and risk factors for Tranexamic acid
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Tranexamic acid | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Tranexamic acid (commonly marketed as Cyklokapron in the U.S. and as Transamin in Asia) is often prescribed for excessive bleeding. It is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, a molecule responsible for the degradation of fibrin. Fibrin is the basic framework for the formation of a blood clot in hemostasis. It has roughly 8 times the antifibrinolytic activity of an older analogue, ε-aminoacaproic acid.
Therapeutic uses
Menstrual bleeding
Tranexamic acid (cyklokapron, transamin) is a synthetic derivative of the amino acid lysine. It exerts its antifibrinolytic effect through the reversible blockade of lysine binding sites on plasminogen molecules [1]. It inhibits endometrial plasminogen activator and thus prevents fibrinolysis and the breakdown of clot. Side effects are uncommon. While prolonged treatment may heighten the risk of an increased thrombotic tendency, such as deep vein thrombosis, large scale studies reveal that the incidence of thrombosis in women treated by tranexamic acid is no different from the spontaneous incidence of thrombosis in women.
Tranexamic acid is used as firstline nonhormonal treatment of dysfunctional uterine bleeding, and heavy bleeding associated with uterine fibroids. A recent study [1] showed that patients treated with tranexamic acid are more likely to develop thrombosis and necrosis in their fibroids, and may result in pain and fever. Moreover, the histological appearance of the necrosis in these drug-related fibroids may be mistaken for smooth muscle tumors of uncertain malignant potential.
Haemophilia
Tranexamic acid is also useful in the treatment of bleeding as a second line treatment next to factor VIII in haemophilia patients (i.e. Tooth extraction in haemophilia patients.)
Angioedema
In acquired angioedema types I and II and non-histaminergic angioedema, antifibrinolytics such as tranexamic acid or ε-aminocaproic acid may be effective.
Cardiac surgery
Tranexamic acid is used in cardiac surgery, e.g. coronary artery bypass surgery, to prevent excessive blood loss.
Orthopedic Surgery
Tranexamic acid is used in orthopedic surgery to reduce bloodloss. It is of proven value in clearing the field of surgery and reducing per and postoperative blood loss. Drain and number of transfusion is reduced. However the hidden blood loss is not reduced. Still it is becoming an important tool in the anaesthetist's arsenal. It is commonly used in joint replacement surgery.
References
Additional Resources
- Tranexamic acid (Dr. P.L.F. Giangrande, Oxford Haemophilia Centre)
- Tranexamic acid (UK patient information leaflet)
- Types of Angioedema and treatments (Hereditary Angioedema Association)
Antihemorrhagics (B02) | |
|---|---|
| Antifibrinolytics | amino acids (Aminocaproic acid, Tranexamic acid, Aminomethylbenzoic acid) - serpins (Aprotinin, Alfa1 antitrypsin, C1-inhibitor, Camostat) |
| Vitamin K | Phytomenadione - Menadione |
| Fibrinogen | Fibrinogen |
| Local hemostatics | Absorbable gelatin sponge - Oxidized cellulose - Tetragalacturonic acid hydroxymethylester - Adrenalone - Thrombin - Collagen - Calcium alginate - Epinephrine |
| Blood coagulation factors | IX - II - VII - X - VIII - Eptacog alfa - Nonacog alfa - Thrombin |
| Other systemic hemostatics | Etamsylate - Carbazochrome - Batroxobin |
it:Acido tranexamico ja:トラネキサム酸
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
